Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) - Findings from the GerHIT multi-centre registry study

Thrombosis Research

Volumn 134, Issue 1, 2014, Pages 29-35

  Schindewolf, Marc ^a   Steindl, Julia ^a   Beyer Westendorf, Jan ^b   Schellong, Sebastian ^c   Dohmen, Pascal Maria ^d   Brachmann, Johannes ^e   Madlener, Katharina ^f   Pötzsch, Bernd ^g   Klamroth, Robert ^h   Hankowitz, Johannes ⁱ   Banik, Norbert ^j   Eberle, Sonja ^j   Kropff, Stefan ^j   Müller, Markus Michael ^j   Lindhoff Last, Edelgard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e KLINIKUM COBURG   (Germany)

^f KERCKHOFF HEART CENTER   (Germany)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

ⁱ Institute of Pharmacology   (Germany)

^j GLAXOSMITHKLINE   (Germany)

more..

Author keywords

Argatroban; Danaparoid; Fondaparinux; Heparin; Heparin induced thrombocytopenia; Lepirudin

Indexed keywords

ARGATROBAN; DANAPAROID; FONDAPARINUX; HEMOGLOBIN; HEPARIN; LEPIRUDIN; THROMBOCYTE FACTOR 4; ANTICOAGULANT AGENT; POLYSACCHARIDE;

4 T HIT PROBABILITY SCORE; ACUTE DISEASE; ADULT; AGED; AMPUTATION; ANTICOAGULANT THERAPY; ARTICLE; ASSAY; BLEEDING; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG INDICATION; ENZYME IMMUNOASSAY; ERYTHEMA; FEMALE; HEMATOTHORAX; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; LABORATORY TEST; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OFF LABEL DRUG USE; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SEROTONIN RELEASE; SKIN DEFECT; SKIN NECROSIS; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; THROMBOCYTOPENIA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; POLYSACCHARIDES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84902548645     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.03.029     Document Type: Article

References (39)

1. J.S. Suh, R.H. Aster, and G.P. Visentin Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4 Blood 91 1998 916 922
2. J.G. Kelton, J.W. Smith, T.E. Warkentin, C.P. Hayward, G.A. Denomme, and P. Horsewood Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4 Blood 83 1994 3232 3239
3. B.H. Chong, I. Fawaz, C.N. Chesterman, and M.C. Berndt Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets Br J Haematol 73 1989 235 240
4. M. Schindewolf, E. Lindhoff-Last, R.J. Ludwig, and W.H. Boehncke Heparin-induced skin lesions Lancet 380 2012 1867 1879
5. M. Schindewolf, H. Kroll, H. Ackermann, J. Garbaraviciene, R. Kaufmann, and W.H. Boehncke et al. Heparin-induced skin lesions: rarely associated with heparin-induced thrombocytopenia J Thromb Haemost 8 2010 1486 1491
6. L.H. Rosenberger, P.W. Smith, R.G. Sawyer, J.B. Hanks, R.B. Adams, and T.L. Hedrick Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia Crit Care Med 39 2011 833 838
7. L.A. Linkins, A.L. Dans, L.K. Moores, R. Bona, B.L. Davidson, and S. Schulman et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e495S e530S
8. T.E. Warkentin, A. Greinacher, A. Koster, and A.M. Lincoff Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 340S 380S
9. M. Schindewolf, B. Luxembourg, and E. Lindhoff-Last Use of fondaparinux in patients with heparin-induced thrombocytopenia type II Vasa 35 2006 70
10. T.E. Warkentin, M. Pai, J.I. Sheppard, S. Schulman, A.C. Spyropoulos, and J.W. Eikelboom Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series J Thromb Haemost 9 2011 2389 2396
11. A.B. Blackmer, M.D. Oertel, and J.M. Valgus Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues Ann Pharmacother 43 2009 1636 1646
12. E. Grouzi, E. Kyriakou, I. Panagou, and I. Spiliotopoulou Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience Clin Appl Thromb Hemost 16 2010 663 667
13. F. Pappalardo, A. Scandroglio, G. Maj, A. Zangrillo, and A. D'Angelo Treatment of heparin-induced thrombocytopenia after cardiac surgery: preliminary experience with fondaparinux J Thorac Cardiovasc Surg 139 2010 790 792
14. B. Lobo, C. Finch, A. Howard, and S. Minhas Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia Thromb Haemost 99 2008 208 214
15. K.H.M. Kuo, and M.J. Kovacs Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux Thromb Haemost 93 2005 999 1000
16. L.E. Efird, and D.R. Kockler Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia Ann Pharmacother 40 2006 1383 1387
17. T.E. Warkentin, B.T. Maurer, and R.H. Aster Heparin-induced thrombocytopenia associated with fondaparinux N Engl J Med 356 2007 2653 2655
18. E. Rota, M. Bazzan, and G. Fantino Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT) Thromb Haemost 99 2008 779 781
19. M. Salem, S. Elrefai, M.A. Shrit, and T.E. Warkentin Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke Thromb Haemost 104 2010 1071 1072
20. M. Burch, and B. Cooper Fondaparinux-associated heparin-induced thrombocytopenia Proc (Bayl Univ Med Cent) 25 2012 13 15
21. T.E. Warkentin, A.K. Chakraborty, J.A. Sheppard, and D.K. Griffin The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome Thromb Haemost 108 2012 394 396
22. T.E. Warkentin, and W. Lim Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal J Thromb Haemost 6 2008 1243 1246
23. I. Elalamy, and B. Tribout Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal J Thromb Haemost 6 2008 1242 1243 [author reply 3-6]
24. M. Schindewolf, and E. Lindhoff-Last Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779-781) Thromb Haemost 100 2008 168 169 [author reply 9-70]
25. T.E. Warkentin Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol 3 2010 567 581
26. A. Greinacher Immunogenic but effective: the HIT-fondaparinux brain puzzler J Thromb Haemost 9 2011 2386 2388
27. J.G. Kelton, D.M. Arnold, and S.M. Bates Nonheparin anticoagulants for heparin-induced thrombocytopenia N Engl J Med 368 2013 737 744
28. G.K. Lo, D. Juhl, T.E. Warkentin, C.S. Sigouin, P. Eichler, and A. Greinacher Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings J Thromb Haemost 4 2006 759 765
29. T.E. Warkentin, and J.G. Kelton Temporal aspects of heparin-induced thrombocytopenia N Engl J Med 344 2001 1286 1292
30. C. Pouplard, P. Gueret, M. Fouassier, C. Ternisien, M. Trossaert, and S. Régina et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia J Thromb Haemost 5 2007 1373 1379
31. T. Bakchoul, A. Giptner, A. Najaoui, G. Bein, S. Santoso, and U.J. Sachs Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia J Thromb Haemost 7 2009 1260 1265
32. S. Baroletti, M. Labreche, M. Niles, J. Fanikos, and S.Z. Goldhaber Prescription of fondaparinux in hospitalised patients Thromb Haemost 101 2009 1091 1094
33. M. Schindewolf, J. Scheuermann, H. Kroll, I. Marzi, R. Kaufmann, and W. Boehncke et al. Application, tolerance and safety of fondaparinux therapy in a German hospital: A prospective single-centre experience Thromb Res 129 2012 17 21
34. M. Schindewolf, R. Kanagendran, J. Scheuermann, H. Ackermann, R. Kaufmann, and W.H. Boehncke et al. Peak and baseline concentrations of fondaparinux during prophylactic therapy. Results of a prospective investigation under "real life" clinical practice conditions Phlebologie 40 2011 187 194
35. S. Baroletti, C. Piovella, and M. Labreche Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes Thromb Haemost 100 2008 1130 1135
36. T. Wilke, S. Tesch, A. Scholz, T. Kohlmann, and A. Greinacher The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis J Thromb Haemost 7 2009 766 773
37. T.E. Warkentin Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls Expert Opin Drug Saf 13 2014 25 43
38. T.E. Warkentin How I, diagnose and manage HIT Hematol Am Soc Hematol Educ Program 2011 2011 143 149
39. T. Furugohri, N. Sugiyama, Y. Morishima, and T. Shibano Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system Thromb Haemost 106 2011 1076 1083